179 related articles for article (PubMed ID: 35461033)
1. Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications.
Kumar A; Chattopadhyay A; Gupta S
Asian J Psychiatr; 2022 Jul; 73():103101. PubMed ID: 35461033
[TBL] [Abstract][Full Text] [Related]
2. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted.
Borah P; Deb PK; Chandrasekaran B; Goyal M; Bansal M; Hussain S; Shinu P; Venugopala KN; Al-Shar'i NA; Deka S; Singh V
Front Mol Biosci; 2021; 8():627723. PubMed ID: 33681293
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
6. Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?
Forero-Peña DA; Hernandez MM; Mozo Herrera IP; Collado Espinal IB; Páez Paz J; Ferro C; Flora-Noda DM; Maricuto AL; Velásquez VL; Camejo-Avila NA; Sordillo EM; Delgado-Noguera LA; Perez-Garcia LA; Morantes Rodríguez CG; Landaeta ME; Paniz-Mondolfi AE
J Med Virol; 2022 Mar; 94(3):1154-1161. PubMed ID: 34755347
[TBL] [Abstract][Full Text] [Related]
7. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
10. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
11. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
12. Medications for early treatment of COVID-19 in Australia.
Polkinghorne A; Branley JM
Med J Aust; 2022 Nov; 217 Suppl 9(Suppl 9):S7-S13. PubMed ID: 36273391
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
14. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R
Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150
[TBL] [Abstract][Full Text] [Related]
15. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
16. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.
Dashraath P; Wong JLJ; Lim MXK; Lim LM; Li S; Biswas A; Choolani M; Mattar C; Su LL
Am J Obstet Gynecol; 2020 Jun; 222(6):521-531. PubMed ID: 32217113
[TBL] [Abstract][Full Text] [Related]
19. Transmission routes of SARS-CoV-2 and protective measures in dental clinics during the COVID-19 pandemic.
Pan Y; Liu H; Chu C; Li X; Liu S; Lu S
Am J Dent; 2020 Jun; 33(3):129-134. PubMed ID: 32470237
[TBL] [Abstract][Full Text] [Related]
20. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
